1. Project Name:	Reimagining Obesity Care Pathways in Greater Manchester Integrated Care System
2. Organisations involved with this Joint Working Project are:	Eli Lilly & Company (Lilly UK) Health Innovation Manchester (HInM)
	This project aims to support optimisation of the obesity pathway by using the results from the project Understanding Obesity Care Pathways in Greater Manchester to identify solutions to improve patient outcomes. By utilising the outputs from Understanding Obesity Care Pathways in Greater Manchester this project aims to provide recommendations to local weight management service commissioners based on multiple service scenario simulations. Simulations will be run testing varying clinical roles and clinic
2. The chiestines for this	formats. The ultimate goal of the project is to identify an alternative, scalable, approach to the management of eligible patients living with obesity throughout the 2 year obesity treatment timeline, and beyond if applicable.
3. The objectives for this project are:	In order to maximise the impact of any weight management interventions, there needs to be an effective and efficient obesity service. This project will support redesigning the obesity pathway with an aim to improve patient outcomes.
	This project will be run as a Collaborative Working Agreement (CWA) in line with Clause 20 of the 2021 ABPI Code of Practice. Any benefits realised from the CWA i.e. improved clinic efficiencies will be realised at an organisational level by Health Innovation Manchester.
	No individual healthcare professional will benefit from the implementation of this Agreement.
	Lilly UK:
4. Roles and Responsibilities, including any funding	 Initial project scoping, design and planning including co-development of project plans and other core project documents. Project management and oversight including stakeholder engagement and management; responsibility for the project plan to ensure completion of milestones within scope, budget and timeframe; communication planning and maintaining project documents Approval of Project Initiation Document (PID) and executive summary and development of Agreement in line with ABPI code of practice requirements. General project administrative support including prepare agendas and issue notices for meetings; ensure all necessary documents requiring discussion or comment are attached to the agenda, distribute the agenda 2 days prior to the meeting. Take action notes of proceedings and prepare minutes of meeting. Distribute the minutes to all members within 3 working days after the meeting

- Pathway redesign support and co-facilitation of Pathway Redesign Group Workshop(s) and subsequent write-up
- Health Economic support to predict system-wide health impact of improved weight management across Greater Manchester ICS, provided by Frontier Economics – a Lilly approved vendor
- Simulation of multiple service scenarios by Tranoca a Lilly approved Vendor
- Support publication of results in appropriate clinical and trade press (draft documentation will be shared with any NHS organisations named in publications for approval)
- Stakeholder engagement support and wider implementation planning with strategic bodies such as ICS and Office for Life Sciences
- Joint publication of project outputs including publication on the Lilly UK corporate website, The ABPI repository and other clinical or trade press.

At no point during this project will Lilly have access to any patient identifiable data.

Lilly will have no input into clinical decision-making for patient eligibility or risk

Health Innovation Manchester:

- Initial project scoping, design and planning including co-development of project plans and other core project documents.
- Responsible for HInM governance process with regards to entering into this agreement
- Understanding of Health Innovation Manchester process for receiving services and funding associated with this Agreement
- Stakeholder management between Health Innovation Manchester, Greater Manchester ICS, Greater Manchester Medicines Management Group
- Baseline data provision through existing databases and / or development of 'gap' data collection plan including provision of a 'test site' to obtain GP data / Trust data
- Clinical and system leadership for baseline data analysis to stratify patients into eligibility and risk
- Clinical and system leadership for pathway redesign
- Commissioning support to ensure alignment of new pathway with current service provision
- Organisation, management and co-facilitation of Pathway Redesign Group Meeting(s)
- Design and Co-ordinate structured interviews with Health Care Professionals to create HCP feedback report
- Dissemination of results including write up for publication in clinical press (following approval from Lilly)
- Provision of relevant and appropriate Health Care Professionals, managerial and administrative staff to attend workshops and provision of remuneration if required

	This project aims to provide recommendations to local weight management
	service commissioners. HInM will not be held responsible if those commissioners choose not to adopt these recommendations
	choose not to adopt these recommendations
	Financial details – Updated December 2023 (the only change from PP-MG-GB-0397)
	Lilly resource costs estimated £131,290
	Health Innovation Manchester resource costs estimated £89,822
5. The expected benefits	Collaborative working – As a minimum the standard of patient care will be
for patients on delivery	maintained. It is expected for an increased volume of patients to benefit from
of this project are:	Obesity services through efficiencies gained at organisation level.
6. The expected benefits	
for the partner	A greater understanding of weight management service opportunities for
organisation(s) on	improvement, and associated workforce impact, efficiencies and health benefits,
delivery of this project	across Greater Manchester.
are:	
7. The expected benefits	An understanding of the benefits of improved/standardised weight management
for Lilly UK on delivery of	services across Greater Manchester which can be translated to learnings across
this are:	the UK. Insights on the appropriate use of obesity licensed medicines in line with
	NICE guidelines.